Kenvue (NYSE:KVUE) Stock Unloaded Rep. Lisa C. McClain

Posted by James Quigley on Nov 29th, 2025

Representative Lisa C. McClain (R-Michigan) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Kenvue Stock Performance

Shares of KVUE stock traded up $0.09 on Friday, hitting $17.31. 9,197,770 shares of the stock traded hands, compared to its average volume of 24,055,314. The company’s fifty day moving average is $16.06 and its 200 day moving average is $19.59. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The company has a market capitalization of $33.15 billion, a PE ratio of 23.07 and a beta of 0.71.

Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s payout ratio is 110.67%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Renaissance Capital LLC boosted its stake in Kenvue by 8.3% during the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after buying an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC raised its position in Kenvue by 80.7% in the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after acquiring an additional 16,164 shares in the last quarter. Arlington Partners LLC acquired a new stake in Kenvue in the 2nd quarter valued at about $2,110,000. Cornell Pochily Investment Advisors Inc. boosted its position in shares of Kenvue by 144.6% during the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after purchasing an additional 19,609 shares in the last quarter. Finally, IFP Advisors Inc boosted its position in shares of Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock valued at $369,000 after purchasing an additional 3,081 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on KVUE shares. Zacks Research upgraded Kenvue to a “strong sell” rating in a research report on Monday, August 11th. Evercore ISI set a $18.00 target price on Kenvue in a research report on Tuesday, October 28th. The Goldman Sachs Group reduced their price target on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, October 2nd. Royal Bank Of Canada dropped their price objective on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a report on Friday, August 8th. Finally, Canaccord Genuity Group reiterated a “hold” rating and issued a $15.00 price objective (down from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $20.23.

Get Our Latest Report on KVUE

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Kenvue

(Get Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.